[Recombinant adenovirus expressing wild-type p53 is antiagiogenic--implication for lung cancer gene therapy].
Angiogenesis is required for the growth and progression of malignancies. Recent studies have demonstrated that genetic alterations may accompany acquisition of the angiogenic phenotype. Here we demonstrate that the recombinant adenovirus-mediated transfer of the wild-type p53 gene into a mutant p53-expressing human non-small cell lung cancer cell line markedly inhibited the expression of an angiogenic factor, vascular endothelial growth factor (VEGF), and increased the expression of a novel antiangiogenic factor, brain-specific angiogenesis inhibitor 1 (BAI 1), resulting in reduced neovascularization in vivo. These results may explain in part the mechanism of the bystander effect induced by wild-type p53 gene transfer of adjacent tumor cells.
Fujiwara
T
T
First Dept. of Surgery, Okayama University Medical School.
Nishizaki
M
M
Tanaka
N
N
D000256:Adenoviridae / Q000235:genetics*; D020533:Angiogenesis Inhibitors; D017209:Apoptosis; D002294:Carcinoma, Squamous Cell / Q000098:blood supply / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D005260:Female; D018014:Gene Transfer Techniques; D016158:Genes, p53; D015316:Genetic Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D008297:Male
D020533:Angiogenesis Inhibitors